Parmax Pharma Ltd

Statement of profit and loss

Parmax Pharma Ltd has not filed a concall transcript in the last 4 quarters.

• 24 Aug 2026

  Filing

  Intimation Of Reclassification Of Promoters Under Regulation 31A Of SEBI (LODR) Regulations, 2015

• 24 Aug 2026

  Filing

  Post Offer Advertisement

• 22 Aug 2026

  Filing

  Receipt Of ''In-Principle'' Approval Under Regulation 28(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Issuance Of Equity Shares And Warrants On Preferential Basis

• 17 Aug 2026

  Filing

  Newspaper Publication

• 17 Aug 2026

  Insider trading

  Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

  Appears 2 times in the recent filings shown; listed once.

• 14 Aug 2026

  Filing

  Change in Management

• 14 Aug 2026

  Results

  Results For Quarter Ended June 30, 2026

• 14 Aug 2026

  Board meeting

  Board Meeting Outcome for Approval Of Unaudited Financial Results For Quarter Ended 30.06.2026

• 14 Aug 2026

  Insider trading

  Disclosures under Reg. 18(6) of SEBI (SAST) Regulations, 2011

• 11 Aug 2026

  Board meeting

  Board Meeting Intimation for Approval Of Quarterly Financial Results For Quarter Ended June 30, 2026

• 29 Jul 2026

  Filing

  Updates on Open Offer

• 27 Jul 2026

  Filing

  Updates on Open Offer

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.